ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD33 | CD33 molecule | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CD4 | CD4 molecule | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
HRH1 | Histamine receptor H1 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
INSR | Insulin receptor | CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK9 | Potassium channel, subfamily K, member 9 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MET | MET proto-oncogene, receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
MMP15 | Matrix metallopeptidase 15 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
MPL | MPL proto-oncogene, thrombopoietin receptor | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Not detected |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PLAUR | Plasminogen activator, urokinase receptor | Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
RARA | Retinoic acid receptor, alpha | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transcription factors
| | | | | Expressed in all |
RET | Ret proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
RRM2 | Ribonucleotide reductase M2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
RRM2B | Ribonucleotide reductase M2 B (TP53 inducible) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
SCNN1D | Sodium channel, non-voltage-gated 1, delta subunit | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SSTR2 | Somatostatin receptor 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
SSTR5 | Somatostatin receptor 5 | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SV2A | Synaptic vesicle glycoprotein 2A | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SYT2 | Synaptotagmin II | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TBXAS1 | Thromboxane A synthase 1 (platelet) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TSPO | Translocator protein (18kDa) | Cancer-related genes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |